Discover our impact all over the world.

Numbers displayed on the map are a representation of the activity in each country. Once you use the filter selections below, you will have the opportunity to explore projects and faculty in each country.

Projects + Faculty = Activity Number



Projects 889
Countries 148
Faculty 445
Health Topics 145

Filter from the selections below

Clear All Filters

HVTN 108: A phase 1/2a clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA, and of MF59®- or AS01B-adjuvanted clade C Env protein in various combinations, in healthy, HIV-uninfected adult participants

The HVTN 108 trial is designed primarily to: Evaluate the safety and tolerability of DNA and/or different doses of clade C bivalent gp120 protein with either MF59 or AS01B adjuvant in various regimens in HIV uninfected healthy adults; and evaluate the systemic immune responses at the Month 6.5 timepoint (2 weeks after the 4th vaccination) of clade C DNA, bivalent gp120 protein/MF59, and/or bivalent gp120 protein/AS01B in each vaccine regimen. 
Funding is provided by HIV Vaccine Trials Network 

Active Dates 
04/01/2017 to 04/30/2018